Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurpiridaz F18 Phase 3 (301)
NCT01347710Phase 3Completed
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Jun 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of Flurpiridaz F 18 in coronary artery disease (CAD), sponsored by Lantheus Holdings, Inc.. Started Jun 2011; status: completed.
02
Drugs
Flurpiridaz F 18
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01347710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01347710.